GlassScriptPhysician profile
Gregory L Henderson
NPI 1427055227
$1,545.51
in general payments reported to CMS, 2019-2025
14 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $724 · 2020: $253 · 2023: $60.33 · 2024: $163 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $568.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $280.11 | 2019-2025 | Clareon, Clareon Panoptix Pro, Argos |
| Sight Sciences, INC. | $239.04 | 2019 | |
| Amgen INC. | $156.00 | 2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $155.23 | 2023-2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $141.17 | 2019 | |
| Glaukos Corporation | $138.43 | 2019 | |
| Rxsight INC | $135.08 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Teva Pharmaceuticals USA, INC. | $89.85 | 2019 | |
| Carl Zeiss Meditec, INC. | $69.04 | 2020 | |
| Janssen Pharmaceuticals, INC | $61.35 | 2019 | |
| Horizon Therapeutics Plc | $27.18 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $17.88 | 2025 | Ryzumvi, Tyrvaya |
| Allergan, INC. | $17.83 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $17.32 | 2025 | Tecnis Iol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Henderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.